Meningococcal Infections: Clinical Trials

119 trials for Meningococcal Infections, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

109 completed, 5 recruiting, 3 unknown, 2 active not recruiting. 119 Phase 3, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3119Completed 109, Recruiting 5, Unknown 3, Active not recruiting 2
Phase 26Completed 4, Recruiting 1, Unknown 1

Follow Meningococcal Infections: new trials by email Literature Review of Meningococcal Infections trials Research Report on Meningococcal Infections

Trials (filtered) newest first · largest first

All 119 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in China
MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA), Menhycia® (ACYW135 Meningococcal Conjugate Vaccine [CRM197]) (CanSino Biologics Inc., China) - Meningococcal Infection, Healthy Volunteers
Phase 3RecruitingSanofi45682026-08-222026-10-19
Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 Months
experimental vaccine, Active Comparator vaccine - Epidemic Meningitis, Meningococcal Vaccines
Phase 3RecruitingSinovac Biotech Co., Ltd8802026-03-252026-08-10
Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months
experimental vaccine, Active Comparator vaccine - Epidemic Meningitis, Meningococcal Vaccines
Phase 3RecruitingSinovac Biotech Co., Ltd10402026-03-222026-08-10
Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 Months
experimental vaccine, Active Comparator vaccine - Epidemic Meningitis, Meningococcal Vaccines
Phase 3RecruitingSinovac Biotech Co., Ltd10402026-03-222026-08-10
Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years
experimental vaccine, active comparator vaccine - Epidemic Meningitis, Meningococcal Vaccines
Phase 3Active not recruitingSinovac Biotech Co., Ltd6602026-03-222026-08-10
Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old
EG-MCV4, Menveo - Meningococcal Infections
Phase 2 / Phase 3RecruitingEyeGene Inc.11232025-10-152025-12-01
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China
MenACYW conjugate vaccine, MenACYW135 polysaccharide vaccine, MenAC conjugate vaccine - Meningococcal Infection, Healthy Volunteers
Phase 3CompletedSanofi16022025-09-262026-10-19
A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds
MCV4, MPSV4 - Meningococcal Meningitis
Phase 3CompletedCanSino Biologics Inc.8402024-12-142026-08-06
A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years
batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4), batch 2 of MCV4, batch 3 of MCV4 - Meningococcal Meningitis
Phase 3CompletedCanSino Biologics Inc.14802024-03-202026-08-06
A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds
MCV4, MPSV4 - Meningococcal Meningitis
Phase 3Active not recruitingCanSino Biologics Inc.8402024-03-012025-07-29
Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in Vietnam
Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine - Meningococcal Infection, Healthy Volunteers
Phase 3CompletedSanofi Pasteur, a Sanofi Company4472024-01-182025-09-17
A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population
MCV4, MSPV4 - Epidemic Meningitis
Phase 3CompletedCanSino Biologics Inc.10002023-09-162025-07-03
Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months
Meningococcal ACYW135 Polysaccharide Conjugate Vaccine, Meningococcal A and C Polysaccharide Conjugate Vaccine - Meningitis, Meningococcal
Phase 3UnknownBeijing Zhifei Lvzhu Biopharmaceutical Co., Ltd12002021-12-182024-04-04
Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine
MenABCWY vaccine, Placebo, MenACWY vaccine - Meningitis, Meningococcal
Phase 3CompletedGlaxoSmithKline12502021-01-252024-07-03
A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide Vaccine
Experimental Group A and C meningococcal polysaccharide vaccine, Control Group A and C meningococcal polysaccharide vaccine - Meningitis, Meningococcal
Phase 3CompletedInstitute of Medical Biology, Chinese Academy of Medical Sciences12802020-09-152026-09-29
A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide Vaccine
Experimental Group A meningococcal polysaccharide vaccine, Control Group A meningococcal polysaccharide vaccine - Meningitis, Meningococcal
Phase 3UnknownWei Cun12802020-09-142020-12-30
Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age
Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ), Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid), Placebo - Infections, Meningococcal
Phase 3CompletedGlaxoSmithKline9452020-08-252025-03-04
Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults
rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY), Placebo - Infections, Meningococcal
Phase 3CompletedGlaxoSmithKline36572020-08-142024-03-05
Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49
Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Blood sample - Meningococcal Infection (Healthy Volunteers)
Phase 3CompletedSanofi Pasteur, a Sanofi Company4712019-10-042025-09-11
Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)
NmCV-5, Menactra - Meningococcal Meningitis
Phase 3CompletedSerum Institute of India Pvt. Ltd.18002019-08-202021-07-27

Showing 20 of 119. Sign in to see all of them.

Narrower conditions

Meningitis, Meningococcal (54)  ·  Meningitis (39)  ·  Haemophilus Infections (6)  ·  Tetanus (6)  ·  Whooping Cough (5)  ·  Chickenpox (4)  ·  Hepatitis B (4)  ·  Measles (4)  ·  Mumps (4)  ·  Rubella (4)  ·  Diphtheria (3)  ·  Central Nervous System Diseases (2)  ·  Fever (2)  ·  Nervous System Diseases (2)

Broader conditions

Bacterial Infections and Mycoses (119)  ·  Neisseriaceae Infections (119)  ·  Bacterial Infections (118)  ·  Gram-Negative Bacterial Infections (118)  ·  Infections (118)  ·  Neuroinflammatory Diseases (74)  ·  Nervous System Diseases (72)  ·  Central Nervous System Diseases (56)  ·  Central Nervous System Infections (56)  ·  Central Nervous System Bacterial Infections (55)  ·  Meningitis, Bacterial (54)  ·  Meningitis (34)  ·  Virus Diseases (11)  ·  DNA Virus Infections (9)

Interventions

Meningococcal Vaccines (27)  ·  MenACWY-CRM vaccine (10)  ·  4CMenB vaccine (9)  ·  13-valent pneumococcal vaccine (8)  ·  Hepatitis B Vaccines (8)  ·  Measles-Mumps-Rubella Vaccine (8)  ·  Tetanus Toxoid (8)  ·  Heptavalent Pneumococcal Conjugate Vaccine (6)  ·  diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (6)  ·  Chickenpox Vaccine (5)  ·  measles, mumps, rubella, varicella vaccine (5)  ·  Blood Specimen Collection (4)  ·  Hepatitis A Vaccines (4)  ·  PEDIARIX (4)  ·  Rotavirus Vaccines (4)

Sponsors

GlaxoSmithKline (34)  ·  Novartis Vaccines (29)  ·  Sanofi Pasteur, a Sanofi Company (25)  ·  Pfizer (7)  ·  Novartis (5)  ·  CanSino Biologics Inc. (4)  ·  Sinovac Biotech Co., Ltd (4)  ·  Sanofi (3)  ·  Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (1)  ·  EyeGene Inc. (1)  ·  Institute of Medical Biology, Chinese Academy of Medical Sciences (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Public Health England (1)  ·  Serum Institute of India Pvt. Ltd. (1)  ·  The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (1)

Countries

United States (31)  ·  Germany (18)  ·  China (13)  ·  Czechia (13)  ·  Finland (13)  ·  Puerto Rico (10)  ·  Spain (10)  ·  Australia (9)  ·  Canada (9)  ·  Italy (9)  ·  Philippines (7)  ·  Mexico (6)  ·  South Korea (6)  ·  Argentina (5)  ·  Chile (5)

Top investigators

Elizabeth Miller, MD (1)  ·  Isti Suharjanti, Dr (1)  ·  Lin Du (1)

Results publications

PMID 23324563, PMID 29253560, PMID 31110098, PMID 33020485, PMID 33325757, PMID 19476428, PMID 19812260, PMID 19895922, PMID 20164251, PMID 20189491, PMID 20655261, PMID 20943209, PMID 21339701, PMID 21343698, PMID 21389149, PMID 22094635, PMID 22260988, PMID 22327493, PMID 22855388, PMID 24873986, PMID 25152325, PMID 25285126, PMID 25305567, PMID 25308927, PMID 25483566, PMID 26075813, PMID 26232542, PMID 26398741, PMID 26479973, PMID 26756390, PMID 26826544, PMID 28318767, PMID 28580917, PMID 29038320, PMID 29784470, PMID 29789243, PMID 29960800, PMID 30068713, PMID 30691980, PMID 30770221, PMID 31116180, PMID 31279564, PMID 31327652, PMID 32209015, PMID 32284274, PMID 32387012, PMID 32552685, PMID 32598244, PMID 32852352, PMID 33814028

NIH funding

2016 (5), 2017 (4), 2019 (4), 2009 (3), 2008 (2), 2014 (2), 2018 (2), 2005 (1)